Drug lookup | Fillwise

Ach-Olmesartan HCTZ · DIN 02468948 · 20mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Ach-Olmesartan HCTZ · DIN 02468948 Manufacturer: Accord Healthcare Inc.; listing date 2019-08-30 Health Canada: Marketed since 2019-06-27 · brand ACH-OLMESARTAN HCTZ · ATC C09DA08 OLMESARTAN MEDOXOMIL AND DIURETICS, C09DA08 OLMESARTAN MEDOXOMIL AND DIURETICS · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 20 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Accord healthcare inc · schedule Prescription

Check this DIN again · Health Canada product record

Ach-Olmesartan HCTZ: Formulary list price $0.3019/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3019 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95759 · Verify on the e-Formulary ↗ (DIN 02468948)

Source record

DIN 02468948: Ach-Olmesartan HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800286; group id 341; item number 0772; lccId None; manufacturer id ACH Source form: Tab; strength: 20mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3019; ministry $0.3019 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02468948 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95759

Interchangeable products

Act Olmesartan HCT · DIN 02443112 · $0.3019 Apo-Olmesartan/HCTZ · DIN 02453606 · $0.3019 Auro-Olmesartan HCTZ · DIN 02476487 · $0.3019 GLN-Olmesartan HCTZ · DIN 02475707 · $0.3019 NRA-Olmesartan HCTZ · DIN 02508273 · $0.3019 Olmesartan/HCTZ · DIN 02509601 · $0.3019 Olmetec Plus · DIN 02319616 · $0.3019 PRZ-Olmesartan/HCTZ · DIN 02526468 · $0.3019

Shortage status: resolved shortage (ended 2026-06-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02468948

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Act Olmesartan HCT · DIN 02443112 · 20mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Act Olmesartan HCT · DIN 02443112 Manufacturer: Teva Canada Limited; listing date 2017-06-29 Health Canada: Marketed since 2023-12-01 · brand TEVA-OLMESARTAN / HCTZ · ATC C09DA08 OLMESARTAN MEDOXOMIL AND DIURETICS, C09DA08 OLMESARTAN MEDOXOMIL AND DIURETICS · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 20 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Teva canada limited · schedule Prescription

Check this DIN again · Health Canada product record

Act Olmesartan HCT: Formulary list price $0.3019/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3019 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92768 · Verify on the e-Formulary ↗ (DIN 02443112)

Source record

DIN 02443112: Act Olmesartan HCT Raw flags: chronicUseMed=Y, sec3=Y Item: 240800286; group id 341; item number 0772; lccId None; manufacturer id TEV Source form: Tab; strength: 20mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3019; ministry $0.3019 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02443112 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92768

Interchangeable products

Ach-Olmesartan HCTZ · DIN 02468948 · $0.3019 Apo-Olmesartan/HCTZ · DIN 02453606 · $0.3019 Auro-Olmesartan HCTZ · DIN 02476487 · $0.3019 GLN-Olmesartan HCTZ · DIN 02475707 · $0.3019 NRA-Olmesartan HCTZ · DIN 02508273 · $0.3019 Olmesartan/HCTZ · DIN 02509601 · $0.3019 Olmetec Plus · DIN 02319616 · $0.3019 PRZ-Olmesartan/HCTZ · DIN 02526468 · $0.3019

Shortage status: discontinued (2025-04-07, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02443112

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Olmesartan HCTZ · DIN 02476487 · 20mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Auro-Olmesartan HCTZ · DIN 02476487 Manufacturer: Auro Pharma Inc.; listing date 2019-11-29 Health Canada: Marketed since 2019-01-29 · brand AURO-OLMESARTAN HCTZ · ATC C09DA08 OLMESARTAN MEDOXOMIL AND DIURETICS, C09DA08 OLMESARTAN MEDOXOMIL AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, OLMESARTAN MEDOXOMIL 20 MG · company Auro pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

Auro-Olmesartan HCTZ: Formulary list price $0.3019/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3019 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96741 · Verify on the e-Formulary ↗ (DIN 02476487)

Source record

DIN 02476487: Auro-Olmesartan HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800286; group id 341; item number 0772; lccId None; manufacturer id AUR Source form: Tab; strength: 20mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3019; ministry $0.3019 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02476487 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96741

Interchangeable products

Ach-Olmesartan HCTZ · DIN 02468948 · $0.3019 Act Olmesartan HCT · DIN 02443112 · $0.3019 Apo-Olmesartan/HCTZ · DIN 02453606 · $0.3019 GLN-Olmesartan HCTZ · DIN 02475707 · $0.3019 NRA-Olmesartan HCTZ · DIN 02508273 · $0.3019 Olmesartan/HCTZ · DIN 02509601 · $0.3019 Olmetec Plus · DIN 02319616 · $0.3019 PRZ-Olmesartan/HCTZ · DIN 02526468 · $0.3019

Shortage status: resolved shortage (ended 2025-01-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02476487

Shortage record checked 2026-09-13T08:10:21.292534+00:00

GLN-Olmesartan HCTZ · DIN 02475707 · 20mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

GLN-Olmesartan HCTZ · DIN 02475707 Manufacturer: Glenmark Pharmaceuticals Canada Inc.; listing date 2021-04-30 Health Canada: Marketed since 2020-02-28 · brand GLN-OLMESARTAN HCTZ · ATC C09DA08 OLMESARTAN MEDOXOMIL AND DIURETICS, C09DA08 OLMESARTAN MEDOXOMIL AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, OLMESARTAN MEDOXOMIL 20 MG · company Glenmark pharmaceuticals canada inc. · schedule Prescription

Check this DIN again · Health Canada product record

GLN-Olmesartan HCTZ: Formulary list price $0.3019/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3019 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96608 · Verify on the e-Formulary ↗ (DIN 02475707)

Source record

DIN 02475707: GLN-Olmesartan HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800286; group id 341; item number 0772; lccId None; manufacturer id GLP Source form: Tab; strength: 20mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3019; ministry $0.3019 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02475707 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96608

Interchangeable products

Ach-Olmesartan HCTZ · DIN 02468948 · $0.3019 Act Olmesartan HCT · DIN 02443112 · $0.3019 Apo-Olmesartan/HCTZ · DIN 02453606 · $0.3019 Auro-Olmesartan HCTZ · DIN 02476487 · $0.3019 NRA-Olmesartan HCTZ · DIN 02508273 · $0.3019 Olmesartan/HCTZ · DIN 02509601 · $0.3019 Olmetec Plus · DIN 02319616 · $0.3019 PRZ-Olmesartan/HCTZ · DIN 02526468 · $0.3019

Shortage status: resolved shortage (ended 2025-09-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02475707

Shortage record checked 2026-09-13T08:10:21.292534+00:00

NRA-Olmesartan HCTZ · DIN 02508273 · 20mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

NRA-Olmesartan HCTZ · DIN 02508273 Manufacturer: Nora Pharma; listing date 2021-10-29 Health Canada: Marketed since 2021-07-20 · brand NRA-OLMESARTAN HCTZ · ATC C09DA08 OLMESARTAN MEDOXOMIL AND DIURETICS, C09DA08 OLMESARTAN MEDOXOMIL AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, OLMESARTAN MEDOXOMIL 20 MG · company Nora pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

NRA-Olmesartan HCTZ: Formulary list price $0.3019/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3019 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99766 · Verify on the e-Formulary ↗ (DIN 02508273)

Source record

DIN 02508273: NRA-Olmesartan HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800286; group id 341; item number 0772; lccId None; manufacturer id NRA Source form: Tab; strength: 20mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3019; ministry $0.3019 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02508273 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99766

Interchangeable products

Ach-Olmesartan HCTZ · DIN 02468948 · $0.3019 Act Olmesartan HCT · DIN 02443112 · $0.3019 Apo-Olmesartan/HCTZ · DIN 02453606 · $0.3019 Auro-Olmesartan HCTZ · DIN 02476487 · $0.3019 GLN-Olmesartan HCTZ · DIN 02475707 · $0.3019 Olmesartan/HCTZ · DIN 02509601 · $0.3019 Olmetec Plus · DIN 02319616 · $0.3019 PRZ-Olmesartan/HCTZ · DIN 02526468 · $0.3019

Shortage status: active shortage (reported 2025-02-10, last updated 2025-04-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02508273

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Olmesartan/HCTZ · DIN 02509601 · 20mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Olmesartan/HCTZ · DIN 02509601 Manufacturer: Sanis Health Inc.; listing date 2021-08-31 Health Canada: Marketed since 2026-04-07 · brand OLMESARTAN/HCTZ · ATC C09DA08 OLMESARTAN MEDOXOMIL AND DIURETICS, C09DA08 OLMESARTAN MEDOXOMIL AND DIURETICS · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 20 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Sanis health inc · schedule Prescription

Check this DIN again · Health Canada product record

Olmesartan/HCTZ: Formulary list price $0.3019/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3019 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99889 · Verify on the e-Formulary ↗ (DIN 02509601)

Source record

DIN 02509601: Olmesartan/HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800286; group id 341; item number 0772; lccId None; manufacturer id SAI Source form: Tab; strength: 20mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3019; ministry $0.3019 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02509601 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99889

Interchangeable products

Ach-Olmesartan HCTZ · DIN 02468948 · $0.3019 Act Olmesartan HCT · DIN 02443112 · $0.3019 Apo-Olmesartan/HCTZ · DIN 02453606 · $0.3019 Auro-Olmesartan HCTZ · DIN 02476487 · $0.3019 GLN-Olmesartan HCTZ · DIN 02475707 · $0.3019 NRA-Olmesartan HCTZ · DIN 02508273 · $0.3019 Olmetec Plus · DIN 02319616 · $0.3019 PRZ-Olmesartan/HCTZ · DIN 02526468 · $0.3019

Shortage status: resolved shortage (ended 2026-04-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02509601

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Olmetec Plus · DIN 02319616 · 20mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Olmetec Plus · DIN 02319616 Manufacturer: Organon Canada Inc.; listing date 2010-04-23 Health Canada: Marketed since 2022-10-31 · brand OLMETEC PLUS · ATC C09DA08 OLMESARTAN MEDOXOMIL AND DIURETICS, C09DA08 OLMESARTAN MEDOXOMIL AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, OLMESARTAN MEDOXOMIL 20 MG · company Organon canada inc. · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $0.3019 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80508 · Verify on the e-Formulary ↗ (DIN 02319616)

Source record

DIN 02319616: Olmetec Plus Raw flags: chronicUseMed=Y, sec3=Y Item: 240800286; group id 341; item number 0772; lccId None; manufacturer id OCI Source form: Tab; strength: 20mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.4693; ministry $0.3019 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02319616 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80508

Interchangeable products

Ach-Olmesartan HCTZ · DIN 02468948 · $0.3019 Act Olmesartan HCT · DIN 02443112 · $0.3019 Apo-Olmesartan/HCTZ · DIN 02453606 · $0.3019 Auro-Olmesartan HCTZ · DIN 02476487 · $0.3019 GLN-Olmesartan HCTZ · DIN 02475707 · $0.3019 NRA-Olmesartan HCTZ · DIN 02508273 · $0.3019 Olmesartan/HCTZ · DIN 02509601 · $0.3019 PRZ-Olmesartan/HCTZ · DIN 02526468 · $0.3019

Shortage status: resolved shortage (ended 2020-07-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02319616

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ach-Olmesartan HCTZ · DIN 02468956 · 40mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Ach-Olmesartan HCTZ · DIN 02468956 Manufacturer: Accord Healthcare Inc.; listing date 2019-08-30 Health Canada: Marketed since 2019-06-27 · brand ACH-OLMESARTAN HCTZ · ATC C09DA08 OLMESARTAN MEDOXOMIL AND DIURETICS, C09DA08 OLMESARTAN MEDOXOMIL AND DIURETICS · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 40 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Accord healthcare inc · schedule Prescription

Check this DIN again · Health Canada product record

Ach-Olmesartan HCTZ: Formulary list price $0.3019/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3019 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95760 · Verify on the e-Formulary ↗ (DIN 02468956)

Source record

DIN 02468956: Ach-Olmesartan HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800287; group id 341; item number 0773; lccId None; manufacturer id ACH Source form: Tab; strength: 40mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3019; ministry $0.3019 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02468956 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95760

Interchangeable products

Act Olmesartan HCT · DIN 02443120 · $0.3019 Apo-Olmesartan/HCTZ · DIN 02453614 · $0.3019 Auro-Olmesartan HCTZ · DIN 02476495 · $0.3019 GLN-Olmesartan HCTZ · DIN 02475715 · $0.3019 NRA-Olmesartan HCTZ · DIN 02508281 · $0.3019 Olmesartan/HCTZ · DIN 02509636 · $0.3019 Olmetec Plus · DIN 02319624 · $0.3019 PRZ-Olmesartan/HCTZ · DIN 02526476 · $0.3019

Shortage status: resolved shortage (ended 2026-05-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02468956

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ach-Olmesartan HCTZ · DIN 02468964 · 40mg & 25mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Ach-Olmesartan HCTZ · DIN 02468964 Manufacturer: Accord Healthcare Inc.; listing date 2019-08-30 Health Canada: Marketed since 2019-06-27 · brand ACH-OLMESARTAN HCTZ · ATC C09DA08 OLMESARTAN MEDOXOMIL AND DIURETICS, C09DA08 OLMESARTAN MEDOXOMIL AND DIURETICS · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 40 MG, HYDROCHLOROTHIAZIDE 25 MG · company Accord healthcare inc · schedule Prescription

Check this DIN again · Health Canada product record

Ach-Olmesartan HCTZ: Formulary list price $0.3019/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3019 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95761 · Verify on the e-Formulary ↗ (DIN 02468964)

Source record

DIN 02468964: Ach-Olmesartan HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800288; group id 341; item number 0774; lccId None; manufacturer id ACH Source form: Tab; strength: 40mg & 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3019; ministry $0.3019 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02468964 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95761

Interchangeable products

Act Olmesartan HCT · DIN 02443139 · $0.3019 Apo-Olmesartan/HCTZ · DIN 02453622 · $0.3019 Auro-Olmesartan HCTZ · DIN 02476509 · $0.3019 GLN-Olmesartan HCTZ · DIN 02475723 · $0.3019 NRA-Olmesartan HCTZ · DIN 02508303 · $0.3019 Olmesartan/HCTZ · DIN 02509628 · $0.3019 Olmetec Plus · DIN 02319632 · $0.3019 PRZ-Olmesartan/HCTZ · DIN 02526484 · $0.3019

Shortage status: resolved shortage (ended 2026-05-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02468964

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Act Olmesartan HCT · DIN 02443120 · 40mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Act Olmesartan HCT · DIN 02443120 Manufacturer: Teva Canada Limited; listing date 2017-06-29 Health Canada: Marketed since 2023-12-01 · brand TEVA-OLMESARTAN / HCTZ · ATC C09DA08 OLMESARTAN MEDOXOMIL AND DIURETICS, C09DA08 OLMESARTAN MEDOXOMIL AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, OLMESARTAN MEDOXOMIL 40 MG · company Teva canada limited · schedule Prescription

Check this DIN again · Health Canada product record

Act Olmesartan HCT: Formulary list price $0.3019/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3019 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92771 · Verify on the e-Formulary ↗ (DIN 02443120)

Source record

DIN 02443120: Act Olmesartan HCT Raw flags: chronicUseMed=Y, sec3=Y Item: 240800287; group id 341; item number 0773; lccId None; manufacturer id TEV Source form: Tab; strength: 40mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3019; ministry $0.3019 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02443120 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92771

Interchangeable products

Ach-Olmesartan HCTZ · DIN 02468956 · $0.3019 Apo-Olmesartan/HCTZ · DIN 02453614 · $0.3019 Auro-Olmesartan HCTZ · DIN 02476495 · $0.3019 GLN-Olmesartan HCTZ · DIN 02475715 · $0.3019 NRA-Olmesartan HCTZ · DIN 02508281 · $0.3019 Olmesartan/HCTZ · DIN 02509636 · $0.3019 Olmetec Plus · DIN 02319624 · $0.3019 PRZ-Olmesartan/HCTZ · DIN 02526476 · $0.3019

Shortage status: discontinued (2025-04-07, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02443120

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Act Olmesartan HCT · DIN 02443139 · 40mg & 25mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Act Olmesartan HCT · DIN 02443139 Manufacturer: Teva Canada Limited; listing date 2017-06-29 Health Canada: Marketed since 2023-12-01 · brand TEVA-OLMESARTAN / HCTZ · ATC C09DA08 OLMESARTAN MEDOXOMIL AND DIURETICS, C09DA08 OLMESARTAN MEDOXOMIL AND DIURETICS · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 40 MG, HYDROCHLOROTHIAZIDE 25 MG · company Teva canada limited · schedule Prescription

Check this DIN again · Health Canada product record

Act Olmesartan HCT: Formulary list price $0.3019/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3019 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92772 · Verify on the e-Formulary ↗ (DIN 02443139)

Source record

DIN 02443139: Act Olmesartan HCT Raw flags: chronicUseMed=Y, sec3=Y Item: 240800288; group id 341; item number 0774; lccId None; manufacturer id TEV Source form: Tab; strength: 40mg & 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3019; ministry $0.3019 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02443139 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92772

Interchangeable products

Ach-Olmesartan HCTZ · DIN 02468964 · $0.3019 Apo-Olmesartan/HCTZ · DIN 02453622 · $0.3019 Auro-Olmesartan HCTZ · DIN 02476509 · $0.3019 GLN-Olmesartan HCTZ · DIN 02475723 · $0.3019 NRA-Olmesartan HCTZ · DIN 02508303 · $0.3019 Olmesartan/HCTZ · DIN 02509628 · $0.3019 Olmetec Plus · DIN 02319632 · $0.3019 PRZ-Olmesartan/HCTZ · DIN 02526484 · $0.3019

Shortage status: discontinued (2025-04-07, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02443139

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Olmesartan HCTZ · DIN 02476495 · 40mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Auro-Olmesartan HCTZ · DIN 02476495 Manufacturer: Auro Pharma Inc.; listing date 2019-11-29 Health Canada: Marketed since 2019-01-29 · brand AURO-OLMESARTAN HCTZ · ATC C09DA08 OLMESARTAN MEDOXOMIL AND DIURETICS, C09DA08 OLMESARTAN MEDOXOMIL AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, OLMESARTAN MEDOXOMIL 40 MG · company Auro pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

Auro-Olmesartan HCTZ: Formulary list price $0.3019/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3019 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96742 · Verify on the e-Formulary ↗ (DIN 02476495)

Source record

DIN 02476495: Auro-Olmesartan HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800287; group id 341; item number 0773; lccId None; manufacturer id AUR Source form: Tab; strength: 40mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3019; ministry $0.3019 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02476495 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96742

Interchangeable products

Ach-Olmesartan HCTZ · DIN 02468956 · $0.3019 Act Olmesartan HCT · DIN 02443120 · $0.3019 Apo-Olmesartan/HCTZ · DIN 02453614 · $0.3019 GLN-Olmesartan HCTZ · DIN 02475715 · $0.3019 NRA-Olmesartan HCTZ · DIN 02508281 · $0.3019 Olmesartan/HCTZ · DIN 02509636 · $0.3019 Olmetec Plus · DIN 02319624 · $0.3019 PRZ-Olmesartan/HCTZ · DIN 02526476 · $0.3019

Shortage status: resolved shortage (ended 2024-01-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02476495

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Olmesartan HCTZ · DIN 02476509 · 40mg & 25mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Auro-Olmesartan HCTZ · DIN 02476509 Manufacturer: Auro Pharma Inc.; listing date 2019-11-29 Health Canada: Marketed since 2019-01-29 · brand AURO-OLMESARTAN HCTZ · ATC C09DA08 OLMESARTAN MEDOXOMIL AND DIURETICS, C09DA08 OLMESARTAN MEDOXOMIL AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 25 MG, OLMESARTAN MEDOXOMIL 40 MG · company Auro pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

Auro-Olmesartan HCTZ: Formulary list price $0.3019/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3019 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96743 · Verify on the e-Formulary ↗ (DIN 02476509)

Source record

DIN 02476509: Auro-Olmesartan HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800288; group id 341; item number 0774; lccId None; manufacturer id AUR Source form: Tab; strength: 40mg & 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3019; ministry $0.3019 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02476509 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96743

Interchangeable products

Ach-Olmesartan HCTZ · DIN 02468964 · $0.3019 Act Olmesartan HCT · DIN 02443139 · $0.3019 Apo-Olmesartan/HCTZ · DIN 02453622 · $0.3019 GLN-Olmesartan HCTZ · DIN 02475723 · $0.3019 NRA-Olmesartan HCTZ · DIN 02508303 · $0.3019 Olmesartan/HCTZ · DIN 02509628 · $0.3019 Olmetec Plus · DIN 02319632 · $0.3019 PRZ-Olmesartan/HCTZ · DIN 02526484 · $0.3019

Shortage status: resolved shortage (ended 2025-01-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02476509

Shortage record checked 2026-09-13T08:10:21.292534+00:00

GLN-Olmesartan HCTZ · DIN 02475715 · 40mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

GLN-Olmesartan HCTZ · DIN 02475715 Manufacturer: Glenmark Pharmaceuticals Canada Inc.; listing date 2021-04-30 Health Canada: Marketed since 2020-02-28 · brand GLN-OLMESARTAN HCTZ · ATC C09DA08 OLMESARTAN MEDOXOMIL AND DIURETICS, C09DA08 OLMESARTAN MEDOXOMIL AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, OLMESARTAN MEDOXOMIL 40 MG · company Glenmark pharmaceuticals canada inc. · schedule Prescription

Check this DIN again · Health Canada product record

GLN-Olmesartan HCTZ: Formulary list price $0.3019/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3019 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96609 · Verify on the e-Formulary ↗ (DIN 02475715)

Source record

DIN 02475715: GLN-Olmesartan HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800287; group id 341; item number 0773; lccId None; manufacturer id GLP Source form: Tab; strength: 40mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3019; ministry $0.3019 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02475715 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96609

Interchangeable products

Ach-Olmesartan HCTZ · DIN 02468956 · $0.3019 Act Olmesartan HCT · DIN 02443120 · $0.3019 Apo-Olmesartan/HCTZ · DIN 02453614 · $0.3019 Auro-Olmesartan HCTZ · DIN 02476495 · $0.3019 NRA-Olmesartan HCTZ · DIN 02508281 · $0.3019 Olmesartan/HCTZ · DIN 02509636 · $0.3019 Olmetec Plus · DIN 02319624 · $0.3019 PRZ-Olmesartan/HCTZ · DIN 02526476 · $0.3019

Shortage status: resolved shortage (ended 2026-04-06); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02475715

Shortage record checked 2026-09-13T08:10:21.292534+00:00

GLN-Olmesartan HCTZ · DIN 02475723 · 40mg & 25mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

GLN-Olmesartan HCTZ · DIN 02475723 Manufacturer: Glenmark Pharmaceuticals Canada Inc.; listing date 2021-04-30 Health Canada: Marketed since 2020-02-28 · brand GLN-OLMESARTAN HCTZ · ATC C09DA08 OLMESARTAN MEDOXOMIL AND DIURETICS, C09DA08 OLMESARTAN MEDOXOMIL AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 25 MG, OLMESARTAN MEDOXOMIL 40 MG · company Glenmark pharmaceuticals canada inc. · schedule Prescription

Check this DIN again · Health Canada product record

GLN-Olmesartan HCTZ: Formulary list price $0.3019/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3019 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96610 · Verify on the e-Formulary ↗ (DIN 02475723)

Source record

DIN 02475723: GLN-Olmesartan HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800288; group id 341; item number 0774; lccId None; manufacturer id GLP Source form: Tab; strength: 40mg & 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3019; ministry $0.3019 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02475723 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96610

Interchangeable products

Ach-Olmesartan HCTZ · DIN 02468964 · $0.3019 Act Olmesartan HCT · DIN 02443139 · $0.3019 Apo-Olmesartan/HCTZ · DIN 02453622 · $0.3019 Auro-Olmesartan HCTZ · DIN 02476509 · $0.3019 NRA-Olmesartan HCTZ · DIN 02508303 · $0.3019 Olmesartan/HCTZ · DIN 02509628 · $0.3019 Olmetec Plus · DIN 02319632 · $0.3019 PRZ-Olmesartan/HCTZ · DIN 02526484 · $0.3019

Shortage status: resolved shortage (ended 2026-03-26); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02475723

Shortage record checked 2026-09-13T08:10:21.292534+00:00

NRA-Olmesartan HCTZ · DIN 02508281 · 40mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

NRA-Olmesartan HCTZ · DIN 02508281 Manufacturer: Nora Pharma; listing date 2021-10-29 Health Canada: Marketed since 2021-07-20 · brand NRA-OLMESARTAN HCTZ · ATC C09DA08 OLMESARTAN MEDOXOMIL AND DIURETICS, C09DA08 OLMESARTAN MEDOXOMIL AND DIURETICS · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 40 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Nora pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

NRA-Olmesartan HCTZ: Formulary list price $0.3019/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3019 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99767 · Verify on the e-Formulary ↗ (DIN 02508281)

Source record

DIN 02508281: NRA-Olmesartan HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800287; group id 341; item number 0773; lccId None; manufacturer id NRA Source form: Tab; strength: 40mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3019; ministry $0.3019 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02508281 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99767

Interchangeable products

Ach-Olmesartan HCTZ · DIN 02468956 · $0.3019 Act Olmesartan HCT · DIN 02443120 · $0.3019 Apo-Olmesartan/HCTZ · DIN 02453614 · $0.3019 Auro-Olmesartan HCTZ · DIN 02476495 · $0.3019 GLN-Olmesartan HCTZ · DIN 02475715 · $0.3019 Olmesartan/HCTZ · DIN 02509636 · $0.3019 Olmetec Plus · DIN 02319624 · $0.3019 PRZ-Olmesartan/HCTZ · DIN 02526476 · $0.3019

Shortage status: active shortage (reported 2024-12-16, last updated 2025-04-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02508281

Shortage record checked 2026-09-13T08:10:21.292534+00:00

NRA-Olmesartan HCTZ · DIN 02508303 · 40mg & 25mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

NRA-Olmesartan HCTZ · DIN 02508303 Manufacturer: Nora Pharma; listing date 2021-10-29 Health Canada: Marketed since 2021-07-20 · brand NRA-OLMESARTAN HCTZ · ATC C09DA08 OLMESARTAN MEDOXOMIL AND DIURETICS, C09DA08 OLMESARTAN MEDOXOMIL AND DIURETICS · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 40 MG, HYDROCHLOROTHIAZIDE 25 MG · company Nora pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

NRA-Olmesartan HCTZ: Formulary list price $0.3019/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3019 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99768 · Verify on the e-Formulary ↗ (DIN 02508303)

Source record

DIN 02508303: NRA-Olmesartan HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800288; group id 341; item number 0774; lccId None; manufacturer id NRA Source form: Tab; strength: 40mg & 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3019; ministry $0.3019 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02508303 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99768

Interchangeable products

Ach-Olmesartan HCTZ · DIN 02468964 · $0.3019 Act Olmesartan HCT · DIN 02443139 · $0.3019 Apo-Olmesartan/HCTZ · DIN 02453622 · $0.3019 Auro-Olmesartan HCTZ · DIN 02476509 · $0.3019 GLN-Olmesartan HCTZ · DIN 02475723 · $0.3019 Olmesartan/HCTZ · DIN 02509628 · $0.3019 Olmetec Plus · DIN 02319632 · $0.3019 PRZ-Olmesartan/HCTZ · DIN 02526484 · $0.3019

Shortage status: active shortage (reported not recorded, last updated 2025-04-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02508303

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Olmesartan/HCTZ · DIN 02509628 · 40mg & 25mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Olmesartan/HCTZ · DIN 02509628 Manufacturer: Sanis Health Inc.; listing date 2021-08-31 Health Canada: Marketed since 2026-04-13 · brand OLMESARTAN/HCTZ · ATC C09DA08 OLMESARTAN MEDOXOMIL AND DIURETICS, C09DA08 OLMESARTAN MEDOXOMIL AND DIURETICS · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 40 MG, HYDROCHLOROTHIAZIDE 25 MG · company Sanis health inc · schedule Prescription

Check this DIN again · Health Canada product record

Olmesartan/HCTZ: Formulary list price $0.3019/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3019 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99890 · Verify on the e-Formulary ↗ (DIN 02509628)

Source record

DIN 02509628: Olmesartan/HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800288; group id 341; item number 0774; lccId None; manufacturer id SAI Source form: Tab; strength: 40mg & 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3019; ministry $0.3019 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02509628 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99890

Interchangeable products

Ach-Olmesartan HCTZ · DIN 02468964 · $0.3019 Act Olmesartan HCT · DIN 02443139 · $0.3019 Apo-Olmesartan/HCTZ · DIN 02453622 · $0.3019 Auro-Olmesartan HCTZ · DIN 02476509 · $0.3019 GLN-Olmesartan HCTZ · DIN 02475723 · $0.3019 NRA-Olmesartan HCTZ · DIN 02508303 · $0.3019 Olmetec Plus · DIN 02319632 · $0.3019 PRZ-Olmesartan/HCTZ · DIN 02526484 · $0.3019

Shortage status: resolved shortage (ended 2026-04-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02509628

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Olmesartan/HCTZ · DIN 02509636 · 40mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Olmesartan/HCTZ · DIN 02509636 Manufacturer: Sanis Health Inc.; listing date 2021-08-31 Health Canada: Marketed since 2026-04-13 · brand OLMESARTAN/HCTZ · ATC C09DA08 OLMESARTAN MEDOXOMIL AND DIURETICS, C09DA08 OLMESARTAN MEDOXOMIL AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, OLMESARTAN MEDOXOMIL 40 MG · company Sanis health inc · schedule Prescription

Check this DIN again · Health Canada product record

Olmesartan/HCTZ: Formulary list price $0.3019/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3019 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99891 · Verify on the e-Formulary ↗ (DIN 02509636)

Source record

DIN 02509636: Olmesartan/HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800287; group id 341; item number 0773; lccId None; manufacturer id SAI Source form: Tab; strength: 40mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3019; ministry $0.3019 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02509636 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99891

Interchangeable products

Ach-Olmesartan HCTZ · DIN 02468956 · $0.3019 Act Olmesartan HCT · DIN 02443120 · $0.3019 Apo-Olmesartan/HCTZ · DIN 02453614 · $0.3019 Auro-Olmesartan HCTZ · DIN 02476495 · $0.3019 GLN-Olmesartan HCTZ · DIN 02475715 · $0.3019 NRA-Olmesartan HCTZ · DIN 02508281 · $0.3019 Olmetec Plus · DIN 02319624 · $0.3019 PRZ-Olmesartan/HCTZ · DIN 02526476 · $0.3019

Shortage status: resolved shortage (ended 2026-04-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02509636

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Olmetec Plus · DIN 02319624 · 40mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Olmetec Plus · DIN 02319624 Manufacturer: Organon Canada Inc.; listing date 2010-04-23 Health Canada: Marketed since 2023-01-03 · brand OLMETEC PLUS · ATC C09DA08 OLMESARTAN MEDOXOMIL AND DIURETICS, C09DA08 OLMESARTAN MEDOXOMIL AND DIURETICS · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 40 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Organon canada inc. · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $0.3019 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80509 · Verify on the e-Formulary ↗ (DIN 02319624)

Source record

DIN 02319624: Olmetec Plus Raw flags: chronicUseMed=Y, sec3=Y Item: 240800287; group id 341; item number 0773; lccId None; manufacturer id OCI Source form: Tab; strength: 40mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.4693; ministry $0.3019 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02319624 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80509

Interchangeable products

Ach-Olmesartan HCTZ · DIN 02468956 · $0.3019 Act Olmesartan HCT · DIN 02443120 · $0.3019 Apo-Olmesartan/HCTZ · DIN 02453614 · $0.3019 Auro-Olmesartan HCTZ · DIN 02476495 · $0.3019 GLN-Olmesartan HCTZ · DIN 02475715 · $0.3019 NRA-Olmesartan HCTZ · DIN 02508281 · $0.3019 Olmesartan/HCTZ · DIN 02509636 · $0.3019 PRZ-Olmesartan/HCTZ · DIN 02526476 · $0.3019

Shortage status: resolved shortage (ended 2025-09-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02319624

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Olmetec Plus · DIN 02319632 · 40mg & 25mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Olmetec Plus · DIN 02319632 Manufacturer: Organon Canada Inc.; listing date 2010-04-23 Health Canada: Marketed since 2022-12-16 · brand OLMETEC PLUS · ATC C09DA08 OLMESARTAN MEDOXOMIL AND DIURETICS, C09DA08 OLMESARTAN MEDOXOMIL AND DIURETICS · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 40 MG, HYDROCHLOROTHIAZIDE 25 MG · company Organon canada inc. · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $0.3019 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80510 · Verify on the e-Formulary ↗ (DIN 02319632)

Source record

DIN 02319632: Olmetec Plus Raw flags: chronicUseMed=Y, sec3=Y Item: 240800288; group id 341; item number 0774; lccId None; manufacturer id OCI Source form: Tab; strength: 40mg & 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.4693; ministry $0.3019 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02319632 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80510

Interchangeable products

Ach-Olmesartan HCTZ · DIN 02468964 · $0.3019 Act Olmesartan HCT · DIN 02443139 · $0.3019 Apo-Olmesartan/HCTZ · DIN 02453622 · $0.3019 Auro-Olmesartan HCTZ · DIN 02476509 · $0.3019 GLN-Olmesartan HCTZ · DIN 02475723 · $0.3019 NRA-Olmesartan HCTZ · DIN 02508303 · $0.3019 Olmesartan/HCTZ · DIN 02509628 · $0.3019 PRZ-Olmesartan/HCTZ · DIN 02526484 · $0.3019

Shortage status: resolved shortage (ended 2025-09-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02319632

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Olmesartan/HCTZ · DIN 02453606 · 20mg & 12.5mg · tablet

General benefitDormant since 2025-10-31 · checked 2026-09-02 · What does dormant mean?

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Apo-Olmesartan/HCTZ · DIN 02453606 Manufacturer: Apotex Inc.; listing date 2017-06-29 Health Canada: Dormant since 2025-10-31 · brand APO-OLMESARTAN/HCTZ · ATC C09DA08 OLMESARTAN MEDOXOMIL AND DIURETICS, C09DA08 OLMESARTAN MEDOXOMIL AND DIURETICS · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 20 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Apotex inc · schedule Prescription

Check this DIN again · Health Canada product record

Apo-Olmesartan/HCTZ: Formulary list price $0.3019/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3019 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94016 · Verify on the e-Formulary ↗ (DIN 02453606)

Source record

DIN 02453606: Apo-Olmesartan/HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800286; group id 341; item number 0772; lccId None; manufacturer id APX Source form: Tab; strength: 20mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3019; ministry $0.3019 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02453606 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94016

Interchangeable products

Ach-Olmesartan HCTZ · DIN 02468948 · $0.3019 Act Olmesartan HCT · DIN 02443112 · $0.3019 Auro-Olmesartan HCTZ · DIN 02476487 · $0.3019 GLN-Olmesartan HCTZ · DIN 02475707 · $0.3019 NRA-Olmesartan HCTZ · DIN 02508273 · $0.3019 Olmesartan/HCTZ · DIN 02509601 · $0.3019 Olmetec Plus · DIN 02319616 · $0.3019 PRZ-Olmesartan/HCTZ · DIN 02526468 · $0.3019

Shortage status: active shortage (reported not recorded, last updated 2024-09-16) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02453606

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Dormant since 2025-10-31 — choose a marketed DIN from the same-category list.

PRZ-Olmesartan/HCTZ · DIN 02526468 · 20mg & 12.5mg · tablet

General benefitDormant since 2025-06-25 · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

PRZ-Olmesartan/HCTZ · DIN 02526468 Manufacturer: Pharmaris Canada Inc.; listing date 2022-11-30 Health Canada: Dormant since 2025-06-25 · brand PRZ-OLMESARTAN/HCTZ · ATC C09DA08 OLMESARTAN MEDOXOMIL AND DIURETICS, C09DA08 OLMESARTAN MEDOXOMIL AND DIURETICS · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 20 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Pharmaris canada inc · schedule Prescription

Check this DIN again · Health Canada product record

PRZ-Olmesartan/HCTZ: Formulary list price $0.3019/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3019 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101555 · Verify on the e-Formulary ↗ (DIN 02526468)

Source record

DIN 02526468: PRZ-Olmesartan/HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800286; group id 341; item number 0772; lccId None; manufacturer id PRZ Source form: Tab; strength: 20mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3019; ministry $0.3019 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02526468 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101555

Interchangeable products

Ach-Olmesartan HCTZ · DIN 02468948 · $0.3019 Act Olmesartan HCT · DIN 02443112 · $0.3019 Apo-Olmesartan/HCTZ · DIN 02453606 · $0.3019 Auro-Olmesartan HCTZ · DIN 02476487 · $0.3019 GLN-Olmesartan HCTZ · DIN 02475707 · $0.3019 NRA-Olmesartan HCTZ · DIN 02508273 · $0.3019 Olmesartan/HCTZ · DIN 02509601 · $0.3019 Olmetec Plus · DIN 02319616 · $0.3019

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02526468

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Dormant since 2025-06-25 — choose a marketed DIN from the same-category list.

Apo-Olmesartan/HCTZ · DIN 02453614 · 40mg & 12.5mg · tablet

General benefitDormant since 2025-10-18 · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Apo-Olmesartan/HCTZ · DIN 02453614 Manufacturer: Apotex Inc.; listing date 2017-06-29 Health Canada: Dormant since 2025-10-18 · brand APO-OLMESARTAN/HCTZ · ATC C09DA08 OLMESARTAN MEDOXOMIL AND DIURETICS, C09DA08 OLMESARTAN MEDOXOMIL AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, OLMESARTAN MEDOXOMIL 40 MG · company Apotex inc · schedule Prescription

Check this DIN again · Health Canada product record

Apo-Olmesartan/HCTZ: Formulary list price $0.3019/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3019 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94017 · Verify on the e-Formulary ↗ (DIN 02453614)

Source record

DIN 02453614: Apo-Olmesartan/HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800287; group id 341; item number 0773; lccId None; manufacturer id APX Source form: Tab; strength: 40mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3019; ministry $0.3019 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02453614 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94017

Interchangeable products

Ach-Olmesartan HCTZ · DIN 02468956 · $0.3019 Act Olmesartan HCT · DIN 02443120 · $0.3019 Auro-Olmesartan HCTZ · DIN 02476495 · $0.3019 GLN-Olmesartan HCTZ · DIN 02475715 · $0.3019 NRA-Olmesartan HCTZ · DIN 02508281 · $0.3019 Olmesartan/HCTZ · DIN 02509636 · $0.3019 Olmetec Plus · DIN 02319624 · $0.3019 PRZ-Olmesartan/HCTZ · DIN 02526476 · $0.3019

Shortage status: active shortage (reported 2024-11-12, last updated 2024-11-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02453614

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Dormant since 2025-10-18 — choose a marketed DIN from the same-category list.

Look up one drug

OLMESARTAN MEDOXOMIL & HYDROCHLOROTHIAZIDE

Ach-Olmesartan HCTZ · DIN 02468948 · 20mg & 12.5mg · tablet

Act Olmesartan HCT · DIN 02443112 · 20mg & 12.5mg · tablet

Auro-Olmesartan HCTZ · DIN 02476487 · 20mg & 12.5mg · tablet

GLN-Olmesartan HCTZ · DIN 02475707 · 20mg & 12.5mg · tablet

NRA-Olmesartan HCTZ · DIN 02508273 · 20mg & 12.5mg · tablet

Olmesartan/HCTZ · DIN 02509601 · 20mg & 12.5mg · tablet

Olmetec Plus · DIN 02319616 · 20mg & 12.5mg · tablet

Ach-Olmesartan HCTZ · DIN 02468956 · 40mg & 12.5mg · tablet

Ach-Olmesartan HCTZ · DIN 02468964 · 40mg & 25mg · tablet

Act Olmesartan HCT · DIN 02443120 · 40mg & 12.5mg · tablet

Act Olmesartan HCT · DIN 02443139 · 40mg & 25mg · tablet

Auro-Olmesartan HCTZ · DIN 02476495 · 40mg & 12.5mg · tablet

Auro-Olmesartan HCTZ · DIN 02476509 · 40mg & 25mg · tablet

GLN-Olmesartan HCTZ · DIN 02475715 · 40mg & 12.5mg · tablet

GLN-Olmesartan HCTZ · DIN 02475723 · 40mg & 25mg · tablet

NRA-Olmesartan HCTZ · DIN 02508281 · 40mg & 12.5mg · tablet

NRA-Olmesartan HCTZ · DIN 02508303 · 40mg & 25mg · tablet

Olmesartan/HCTZ · DIN 02509628 · 40mg & 25mg · tablet

Olmesartan/HCTZ · DIN 02509636 · 40mg & 12.5mg · tablet

Olmetec Plus · DIN 02319624 · 40mg & 12.5mg · tablet

Olmetec Plus · DIN 02319632 · 40mg & 25mg · tablet

Apo-Olmesartan/HCTZ · DIN 02453606 · 20mg & 12.5mg · tablet

PRZ-Olmesartan/HCTZ · DIN 02526468 · 20mg & 12.5mg · tablet

Apo-Olmesartan/HCTZ · DIN 02453614 · 40mg & 12.5mg · tablet

Matched class: 24:08 Hypotensive Drugs (For Diuretics See 40:28)

CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE

IRBESARTAN & HYDROCHLOROTHIAZIDE

LOSARTAN POTASSIUM & HYDROCHLOROTHIAZIDE

TELMISARTAN & HYDROCHLOROTHIAZIDE

VALSARTAN & HYDROCHLOROTHIAZIDE

EPROSARTAN MESYLATE & HYDROCHLOROTHIAZIDE

TELMISARTAN & AMLODIPINE BESYLATE

ATENOLOL & CHLORTHALIDONE

BENAZEPRIL

CANDESARTAN CILEXETIL

CAPTOPRIL

CILAZAPRIL

Availability